How should hepatitis C be managed in patients aged 65 years and older? Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 1, 2007, Pages 22-23

  Nourani, Sam ^a   Pockros, Paul J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Antiviral therapy; Biochemical markers; Elderly patients; Hepatitis C; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG RESPONSE; DRUG WITHDRAWAL; ELDERLY CARE; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MONOTHERAPY; PRIORITY JOURNAL; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 33846040186     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0682     Document Type: Short Survey

References (4)

1. Pockros PJ (2006) Noninvasive markers of fibrosis in chronic hepatitis patients. J Clin Gastroenterol 40: 461-463
2. McGill DB et al. (1990) A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99: 1396-1400
3. Poynard T et al. (2004) Overview of the diagnostic value of biochemical markers of liver fibrosis (Fibro Test, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3:8-19
4. Fried MW et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982